Opinion|Videos|March 14, 2025
Optimizing Bispecific Antibody Use: Opportunities to Broaden Patient Access
Experts discuss which patient populations stand to benefit the most from recently approved bispecific therapies, identifying gaps or opportunities for further patient benefit, as well as the data gaps that exist in understanding the optimal use of bispecific antibodies across various cancer types.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What patient populations stand to benefit the most from recently approved bispecific therapies?
- Where are gaps or opportunities for patient populations to further benefit from bispecifics?
- What data gaps exist in understanding the optimal use of bispecific antibodies across various cancer types?
Advertisement
Related to this article
A network meta-analysis found vibegron outperformed mirabegron and tolterodine on several OAB efficacy measures but had higher odds of adverse events.
A US modeling study found tirzepatide and semaglutide cost-effective for MASH, while resmetirom exceeded the $100,000/QALY threshold.
Expert panel discussions covered AI and community access, chronic lymphocytic leukemia, myeloma, and breast and lung cancers.
The analysis found a nonlinear association between systemic inflammation and overactive bladder, with stronger links at higher inflammation levels.
A real-world study found that adding a GLP-1 to SGLT2 inhibitor therapy was associated with lower kidney, cardiovascular, and mortality risks in CKD.
In experiments at MD Anderson, rising CD70 helps mantle cell lymphoma evade immunity; a CD70×CD3 bispecific restores T-cell killing and prolongs survival in resistant models.
Upper-extremity synovial sarcoma required more staged surgery, while lower-extremity disease carried more complications and metastases.
In the US alone, 1.1 million individuals are living with the progressive neurodegenerative movement disorder, and 90,000 are diagnosed each year.
Advertisement
Advertisement
Trending on AJMC
1
Medicare Cap Eases Patient Costs as Negotiation Squeezes Practices
2
Access and Innovation in North Carolina’s Research Triangle
3
An Odyssey of Symptoms, Setbacks, Treatments, and a Cure With CAR T-Cell Therapy
4
PBM Satisfaction Stalls as Net Promoter Score Turns Negative
5